Literature DB >> 7742435

Persistence of Schistosoma haematobium infection despite multiple courses of therapy with praziquantel.

B L Herwaldt1, L F Tao, W van Pelt, V C Tsang, J I Bruce.   

Abstract

A 7-year-old boy, who had returned to the United States in June 1991 after a 3-year stay in Malawi, was evaluated in October 1991 because of hematuria. He was excreting Schistosoma haematobium eggs and was treated with praziquantel (PZQ; approximately 40 mg/kg). He may have spit up < or = 30% of this dose, and a concomitant Giardia lamblia infection might have caused malabsorption of PZQ. Because of persistent excretion of viable eggs, he was retreated with PZQ in January and May 1992. Egg excretion was first quantified 2 months following his second course of PZQ; at that time it was 35 eggs per 10 mL of urine. He excreted viable eggs at least as late as October 1992, 5 months after his third PZQ course. Experimental administration of chemotherapy to hamsters infected with the S. haematobium strain demonstrated that it was susceptible to PZQ. Repeated courses of therapy with PZQ may be necessary to cure S. haematobium infection, and both parasite and host factors should be considered if infection persists.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7742435     DOI: 10.1093/clinids/20.2.309

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

Review 1.  Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance.

Authors:  Nuno Vale; Maria João Gouveia; Gabriel Rinaldi; Paul J Brindley; Fátima Gärtner; José M Correia da Costa
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 2.  Susceptibility or resistance of praziquantel in human schistosomiasis: a review.

Authors:  Wei Wang; Li Wang; You-Sheng Liang
Journal:  Parasitol Res       Date:  2012-10-07       Impact factor: 2.289

3.  The sensitivity of Schistosoma japonicum to praziquantel: a field evaluation in areas with low endemicity of China.

Authors:  Wei Wang; Jian-Rong Dai; Hong-Jun Li; Xue-Hui Shen; You-Sheng Liang
Journal:  Am J Trop Med Hyg       Date:  2012-05       Impact factor: 2.345

4.  Identification of oxadiazoles as new drug leads for the control of schistosomiasis.

Authors:  Ahmed A Sayed; Anton Simeonov; Craig J Thomas; James Inglese; Christopher P Austin; David L Williams
Journal:  Nat Med       Date:  2008-03-16       Impact factor: 53.440

Review 5.  New approaches for understanding mechanisms of drug resistance in schistosomes.

Authors:  Robert M Greenberg
Journal:  Parasitology       Date:  2013-04-03       Impact factor: 3.234

6.  Synthesis of Oxadiazole-2-oxide Analogues as Potential Antischistosomal Agents.

Authors:  Ganesha Rai; Craig J Thomas; William Leister; David J Maloney
Journal:  Tetrahedron Lett       Date:  2009-04       Impact factor: 2.415

Review 7.  Drug treatment of tropical parasitic infections: recent achievements and developments.

Authors:  I Stephenson; M Wiselka
Journal:  Drugs       Date:  2000-11       Impact factor: 11.431

8.  Characterization of the phytochelatin synthase of Schistosoma mansoni.

Authors:  Debalina Ray; David L Williams
Journal:  PLoS Negl Trop Dis       Date:  2011-05-24

Review 9.  Schistosomiasis in Malawi: a systematic review.

Authors:  Peter Makaula; John R Sadalaki; Adamson S Muula; Sekeleghe Kayuni; Samuel Jemu; Paul Bloch
Journal:  Parasit Vectors       Date:  2014-12-10       Impact factor: 3.876

10.  Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen.

Authors:  Samuel Nkansah Darko; Henry Hanson; Sampson Twumasi-Ankrah; Sandra Baffour-Awuah; Priscilla Adjei-Kusi; Denis Yar; Ellis Owusu-Dabo
Journal:  BMC Infect Dis       Date:  2020-05-06       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.